As interest in the future of interventional psychiatry continues to grow, researchers are exploring whether psychedelic therapies may help address some of the most challenging substance use disorders. A new clinical trial suggests that psilocybin for cocaine use disorder may offer a promising new approach when combined with structured psychotherapy.
Cocaine use disorder remains a major public health concern, with many individuals struggling to achieve and maintain long-term abstinence. Existing treatment options often rely on behavioral interventions, but there are currently no US Food and Drug Administration approved medications specifically indicated for cocaine use disorder. This treatment gap has prompted researchers to investigate novel therapeutic strategies.
Current Challenges In Cocaine Use Disorder Treatment
Cocaine use disorder is associated with high rates of relapse, even among individuals who are motivated to stop using the drug. Traditional behavioral therapies can be effective for some patients, but outcomes vary considerably, and sustained recovery often remains difficult.
Researchers have increasingly turned their attention to psychedelic-assisted therapies because of their potential to promote psychological flexibility, emotional insight, and lasting behavioral change. Psilocybin, the psychoactive compound found in certain mushroom species, has already shown promise in studies involving depression, alcohol use disorder, and tobacco addiction.
Testing Psilocybin For Cocaine Use Disorder
To investigate whether these benefits could extend to cocaine addiction, researchers conducted a randomized, quadruple-blind, placebo-controlled clinical trial involving 40 adults diagnosed with cocaine use disorder.
Participants were highly motivated to quit cocaine and were randomly assigned to receive either a single oral dose of psilocybin or an active placebo consisting of diphenhydramine. Both groups participated in a structured psychotherapy program that included cognitive behavioral treatment before and after the medication session.
The study followed participants for 180 days after treatment, allowing investigators to examine both short-term and longer-term outcomes.
Why This Study Design Matters
Addiction treatment studies can be difficult to conduct because participant expectations often influence outcomes. To address this challenge, investigators used an active placebo rather than an inactive substance.
The quadruple-blind design also helped reduce potential bias by ensuring that participants, clinicians, investigators, and outcome assessors remained unaware of treatment assignments.
In addition, cocaine abstinence was verified using both participant reports and urine testing, strengthening confidence in the findings.
Psilocybin For Cocaine Use Disorder Produced Stronger Abstinence Outcomes
The results were notable.
Participants who received psilocybin reported significantly higher percentages of cocaine-free days throughout the follow-up period compared with those who received placebo. Improvements were observed during the immediate integration phase and remained evident through both the 90-day and 180-day assessments.
Researchers also found that 30% of participants in the psilocybin group achieved complete abstinence during the primary follow-up period. By comparison, none of the participants in the placebo group achieved complete abstinence.
Perhaps most importantly, psilocybin treatment was associated with a substantially lower risk for cocaine lapse over time. Survival analyses suggested that individuals who received psilocybin were more likely to maintain abstinence during the months following treatment.
Understanding The Potential Mechanisms
Scientists are still working to understand exactly how psilocybin may influence addiction-related behaviors.
One theory is that psilocybin temporarily enhances brain plasticity, allowing individuals to adopt new perspectives and behavioral patterns. Combined with psychotherapy, this period of heightened flexibility may help patients reexamine deeply ingrained habits and develop healthier coping strategies.
Researchers have also proposed that psychedelic experiences may alter reward processing, self-awareness, and emotional regulation, all of which play important roles in substance use disorders.
What Makes These Findings Different
Several aspects of this study distinguish it from earlier addiction research.
First, benefits were observed after a single psilocybin administration session rather than repeated dosing. Second, the improvements persisted for up to six months following treatment. Finally, the study focused on a population that has historically had limited pharmacological treatment options.
Although adverse events were more common among psilocybin recipients, no serious treatment-related adverse events were reported.
Implications For The Future Of Addiction Treatment
While these findings are encouraging, researchers emphasize that larger studies are necessary before psilocybin can be considered an established treatment for cocaine use disorder.
The accompanying editorial also highlighted the importance of viewing the results within the context of the full treatment program, which included intensive psychotherapy and extensive safety monitoring.
Nevertheless, the study adds to growing evidence that psychedelic-assisted interventions may represent an important frontier in addiction medicine. If future trials confirm these findings, psilocybin for cocaine use disorder could eventually become part of a broader toolkit designed to support long-term recovery and reduce relapse among individuals facing one of the most persistent substance use challenges.
Citations
Hendricks PS, Lappan SN, Shelton RC, et al. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. Available at: https://pubmed.ncbi.nlm.nih.gov/42096204/
Bonar EE. Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder: A Critical Appraisal. 2026;9(5):e2611042. Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848760
Explore more at https://www.interventionalpsychiatry.org/